drugset / Trial / NCT07139535
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal for this study is to evaluate the efficacy and safety of RAY1225 versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
Timeline
- Start
- 2025-08-31
- Primary completion
- 2026-12-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAY1225 | Unknown | 3 mg | Subcutaneous |
| Subject | RAY1225 | Unknown | 6 mg | Subcutaneous |
| Subject | RAY1225 | Unknown | 9 mg | Subcutaneous |